Pyxis Oncology (PYXS) EBIT Margin (2024 - 2025)

Pyxis Oncology (PYXS) posted quarterly EBIT Margin of 165.75% for Q4 2025, up 76.33% quarter-over-quarter from 700.35% in Q2 2025.

Pyxis Oncology (PYXS) EBIT Margin (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has reported EBIT Margin for 2 consecutive years, with 165.75% the latest figure, recorded in Q4 2025.

In Q4 2025, EBIT Margin changed N/A year-over-year to 165.75%; the TTM figure through Dec 2025 stood at 609.18% (down 5511.0% YoY), while the FY2025 annual figure was 609.18%, down 5511.0% from the prior year.
EBIT Margin grew to 165.75% in Q4 2025 per PYXS's latest filing, from 700.35% in the prior quarter.
Across five years, EBIT Margin topped out at 34.71% in Q1 2024 and bottomed at 700.35% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Pyxis Oncology	199.01 Mn	166.02 Mn	-	-

Download Data